Main Semaglutide Patents and Expiry Dates
Semaglutide, the active ingredient in drugs like Ozempic and Wegovy from Novo Nordisk, has multiple patents with staggered expiries. The core composition-of-matter patent (US 8,129,343) covering the molecule expires on December 31, 2031 in the US, after pediatric exclusivity extension.[1][2]
Newer formulation patents, such as US 9,295,689 for the Ozempic autoinjector, extend to March 31, 2033 (with pediatric extension).[1]
When Does Ozempic's Patent Protection End?
Ozempic's key patents include:
- US 8,129,343 (compound): December 31, 2031.
- US 8,536,129 (GLP-1 use): January 31, 2032.
- US 9,295,689 (device): March 31, 2033.
Full market entry for generics likely waits until 2032-2033, pending litigation.[1][2]
Wegovy Patent Timeline Differences
Wegovy shares the semaglutide compound patent (to 2031) but has distinct obesity dosing patents like US 9,474,780, expiring January 1, 2032 (extended).[1][3] Higher-dose pen patents push to 2033+.
Why Multiple Expiry Dates Exist
Novo Nordisk layers patents on the molecule, methods, devices, and formulations, creating "patent thickets." This delays generics beyond the original 2026 compound expiry.[2]
Ongoing Patent Challenges
Mylan (Viatris) and Hims & Hers challenge key semaglutide patents, with FDA tentative approvals for generics as early as 2026 if successful. Novo won some injunctions in 2024, but cases continue in district courts.[1][4]
Biosimilar Entry Possibilities
No true biosimilars yet approved, but 505(b)(2) generics could launch post-2031 if challenges succeed. Europe sees earlier expiry (2026 for compound).[2][3]
Check Latest Status
Patent dates shift with litigation or extensions. Search DrugPatentWatch.com for Ozempic/Wegovy updates.[1]
[1]: DrugPatentWatch.com - Ozempic Patents
[2]: DrugPatentWatch.com - Semaglutide Patents
[3]: DrugPatentWatch.com - Wegovy Patents
[4]: FDA Orange Book and Court Filings